Journal article
Thrombotic microangiopathy associated with proteasome inhibitors
Clinical kidney journal, Vol.8(5), pp.632-636
10/2015
DOI: 10.1093/ckj/sfv059
PMCID: PMC4581378
PMID: 26413293
Abstract
The ubiquitin proteasome pathway plays a key role in cell cycle, function and survival. Bortezomib (BTZ) and Carfilzomib (CFZ) are the first two inhibitors of the proteasome pathway, indicated in treatment of patients with multiple myeloma. In the past few years, there have been few case reports that have highlighted the association between proteasome inhibitors (BTZ and CFZ) with acute kidney injury (AKI). In most of these case reports and initial trials, the underlying mechanism of AKI has been unclear. In this article, we discuss the association and pathogenesis of proteasome inhibitors-associated AKI. We also report the first case of CFZ-associated AKI with kidney biopsy evidence of thrombotic microangiopathy and the presence of microangiopathic hemolytic anemia.
Details
- Title: Subtitle
- Thrombotic microangiopathy associated with proteasome inhibitors
- Creators
- Ahad Lodhi - Department of Nephrology, Internal Medicine , University of Iowa Hospitals and Clinics , Iowa City, IA 52246 , USAAbhishek Kumar - Department of Nephrology, Internal Medicine , University of Iowa Hospitals and Clinics , Iowa City, IA 52246 , USAMuhammad U Saqlain - Department of Nephrology, Internal Medicine , University of Iowa Hospitals and Clinics , Iowa City, IA 52246 , USAManish Suneja - Department of Nephrology, Internal Medicine , University of Iowa Hospitals and Clinics , Iowa City, IA 52246 , USA
- Resource Type
- Journal article
- Publication Details
- Clinical kidney journal, Vol.8(5), pp.632-636
- DOI
- 10.1093/ckj/sfv059
- PMID
- 26413293
- PMCID
- PMC4581378
- NLM abbreviation
- Clin Kidney J
- ISSN
- 2048-8505
- eISSN
- 2048-8513
- Language
- English
- Date published
- 10/2015
- Academic Unit
- Nephrology; Internal Medicine
- Record Identifier
- 9984094379402771
Metrics
9 Record Views